Amylyx Pharmaceuticals, Inc.
AMLX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $87 | $381 | $22 | $0 |
| % Growth | -77.1% | 1,612.9% | – | – |
| Cost of Goods Sold | $42 | $25 | $3 | $0 |
| Gross Profit | $45 | $355 | $19 | $0 |
| % Margin | 51.8% | 93.3% | 86.5% | – |
| R&D Expenses | $104 | $128 | $93 | $44 |
| G&A Expenses | $112 | $179 | $123 | $39 |
| SG&A Expenses | $114 | $188 | $127 | $39 |
| Sales & Mktg Exp. | $3 | $10 | $4 | $0 |
| Other Operating Expenses | $142 | $0 | $0 | -$0 |
| Operating Expenses | $360 | $317 | $221 | $83 |
| Operating Income | -$315 | $39 | -$201 | -$83 |
| % Margin | -360.2% | 10.2% | -905.7% | – |
| Other Income/Exp. Net | $13 | $15 | $4 | -$5 |
| Pre-Tax Income | -$302 | $54 | -$198 | -$88 |
| Tax Expense | -$0 | $5 | $1 | $0 |
| Net Income | -$302 | $49 | -$198 | -$88 |
| % Margin | -345.4% | 12.9% | -892.4% | – |
| EPS | -4.43 | 0.73 | -2.98 | -1.52 |
| % Growth | -706.8% | 124.5% | -96.1% | – |
| EPS Diluted | -4.43 | 0.7 | -2.98 | -1.52 |
| Weighted Avg Shares Out | 68 | 67 | 67 | 58 |
| Weighted Avg Shares Out Dil | 68 | 70 | 67 | 58 |
| Supplemental Information | – | – | – | – |
| Interest Income | $14 | $16 | $4 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $0 | $0 |
| EBITDA | -$291 | $40 | -$201 | -$83 |
| % Margin | -333% | 10.5% | -903.5% | – |